WEST DES MOINES, IA -- (Marketwired) -- 05/20/15 -- Spotlight Innovation Inc. (OTCQB:STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Cris Grunewald, President and CEO of Spotlight Innovation, said, "We are pleased to be moving forward with Celtic Biotech's clinical trial schedule, and to be partnering with a CRO service leader like ImmunoClin. We continue to build value in Celtic Biotech, and to move toward the realization of a product portfolio that will have a positive impact on the health and well-being of as many people as possible."
Dr. Paul Reid, President of Celtic Biotech, said "ImmunoClin's team has formidable experience in the oncology field and they offer unparalleled clinical development expertise. We look forward to working with them."
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB:STLT) specializes in identifying, acquiring and incubating companies which have unique intellectual property (IP) in the medical sector. The Company utilizes relationships with the nation's leading academic and institutional IP developers to locate promising IP technologies with potential for market share capture. With our support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We intend to partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at www.spotlightinnovation.com.
About Celtic Biotech Iowa, Inc.
Celtic Biotech Iowa, Inc., a subsidiary of Spotlight Innovation Inc., is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients. Additional information available at http://www.celticbiotech.com.
About the ImmunoClin Corporation
ImmunoClin Corporation (OTCQB:IMCL) is a United States healthcare company with its principal office in Washington, DC, and European headquarters and laboratories in central London, United Kingdom. IMCL's subsidiary, ImmunoClin Ltd., has been providing quality research and development services to industry for over 14 years. More information available at http://www.immunoclin.com/.
Forward Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
Spotlight Innovation Inc.
Dr. Dorothy Bray, Director, President & CEO
J. Scott Munro, CFO
Mobile: +1 778-987-4308